Publications
73
Citations
16,778
Est. group size
—
Recurring co-author estimate
Active years
52
Publishing since 1974
C. D. Bloomfield's research focuses on blood cancers, particularly acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). This work includes studying genetic markers that help predict how patients will respond to treatment, such as gene mutations (NPM1/FLT3-ITD) and genetic variations affecting drug side effects. The research aims to improve how doctors classify leukemia patients by risk level and select appropriate therapies.
Publication output over the last decade has been very sparse, with only two publications recorded (in 2019 and 2025) and no consistent yearly output.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- PF260 PROGNOSTIC AND PREDICTIVE IMPACT OF NPM1/FLT3-ITD GENOTYPES AS DEFINED BY 2017 EUROPEAN LEUKEMIANET RISK CATEGORIZATION FROM AML PATIENTS TREATED WITHIN THE INTERNATIONAL RATIFY STUDY
HemaSphere · 2019
- Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia
The Pharmacogenomics Journal · 2016
- The Pharmacogenomics Journal×1
- Haematologica×1
- Cancer×1
- HemaSphere×1
- Yosra Ben Youssef
Medicine · The Ohio State University
- Allyson Waller
Medicine · The Ohio State University
- Terri Guinipero
Medicine · The Ohio State University
- Jessica Kohlschmidt
Medicine · The Ohio State University
- Sai Prasad Desikan
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile